专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

KR101870125B1 HMGA2를 이용하여 비신경 세포로부터 리프로그래밍된 유도 신경줄기세포를 제조하는 방법 有权
公开(公告)号：KR101870125B1
公开(公告)日：2018-06-26
申请号：KR1020140040800
申请日：2014-04-04
申请人： 주식회사 강스템바이오텍 , 서울대학교산학협력단
发明人： 강경선 , 유경록
IPC分类号： C12N15/12 , C12N15/85 , C12N5/0797 , C12N5/10
CPC分类号： C12N5/0623 , A61K35/30 , A61K38/1709 , C12N2501/602 , C12N2501/998 , C12N2502/1352 , C12N2506/00 , C12N2506/025 , C12N2510/00 , G01N33/5058
摘要： 본발명은분화된세포로부터리프로그래밍된유도신경줄기세포를제조하는방법에관한것이다. 본발명에의한유도신경줄기세포의생산방법은유도인자로서 SOX2와 HMGA2의 2개유도인자만을이용하여도비신경세포로부터유도신경줄기세포를제작할수 있기때문에, 기존의 4개의인자, 5개의유도인자를이용한생산방법보다더 효율적인유도신경줄기세포를제작할수 있다. 또한 SOX2 유전자 1개만을도입하였을때보다유도효율및 증식력이현저히우수하므로치료목적으로활용가능성이더 높아질수 있다.

2. 发明授权

KR101266771B1 ＤＮＥＲ 또는 이의 활성제를 포함하는 비만 개선용 조성물 有权
标题翻译：用于改善肥胖症的组合物，包括DNER或DNER活化剂
公开(公告)号：KR101266771B1
公开(公告)日：2013-05-28
申请号：KR1020080118932
申请日：2008-11-27
申请人： 서울대학교산학협력단
发明人： 강경선 , 박정란
IPC分类号： A61K38/16 , A61P3/04
摘要： 본발명은 DNER (delta/notch-like EGF-related receptor)의기능적억제가지방생성분화를강화하고지질축적기작을촉진하는사실을규명하고, DNER를정상화또는활성화시키는기작으로비만을개선하거나비만관련질환의치료에이용하기위한방법에관한것이다. 이를위하여, 본발명은 DNER를활성화시키는물질을포함하는비만개선용조성물또는단리된활성형의 DNER 단백질또는이를코딩하는핵산을포함하는비만개선용조성물을제공한다.

3. 发明公开

KR1020100051195A Ｄｋｋ1 또는 ｓＦＲＰ4 억제제를 함유한 비만 예방용 조성물 无效
标题翻译：用于防止含有DKK1或SFRP4的抑制剂的成分的组合物
公开(公告)号：KR1020100051195A
公开(公告)日：2010-05-17
申请号：KR1020080110230
申请日：2008-11-07
申请人： 서울대학교산학협력단
发明人： 강경선 , 박정란
IPC分类号： A61K39/395 , A61P3/04
CPC分类号： A61K35/28 , A61K39/39533 , Y10S514/909
摘要： PURPOSE: An obesity preventive composition containing a Dkk1(dickkopf-related protein 1) OR a sFRP4(secreted frizzled-related protein 4) inhibitor is provided to control the differentiation of MSC to a fat cell. CONSTITUTION: An obesity preventive composition contains a Dkk1 OR a sFRP4 inhibitor. The Dkk1 inhibitor is an antibody for the Dkk1 which expresses a siRNA(small interfering RNA) targeting the Dkk1. The sFRP4 inhibitor is the antibody for the sFRP4 which expresses the siRNA targeting the sFRP4. The differentiation of MSC(mesenchymal stem cells) is inhibited by the Dkk1 or the sFRP4 inhibitor by processing the MSC with the inhibitors for controlling the differentiation into a fat cell.
摘要翻译：目的：提供含有Dkk1（dickkopf相关蛋白1）或sFRP4（分泌性卷曲相关蛋白4）抑制剂的肥胖预防组合物，以控制MSC与脂肪细胞的分化。构成：肥胖预防组合物含有Dkk1 OR或sFRP4抑制剂。 Dkk1抑制剂是Dkk1的抗体，其表达靶向Dkk1的siRNA（小干扰RNA）。 sFRP4抑制剂是表达靶向sFRP4的siRNA的sFRP4的抗体。 MSC（间充质干细胞）的分化被Dkk1或sFRP4抑制剂抑制，通过用控制分化成脂肪细胞的抑制剂处理MSC。

4. 发明公开

KR1020140121787A HMGA2를 이용하여 비신경 세포로부터 리프로그래밍된 유도 신경줄기세포를 제조하는 방법 审中-实审
标题翻译：使用HMGA2从非神经细胞产生复制诱导型神经干细胞的方法
公开(公告)号：KR1020140121787A
公开(公告)日：2014-10-16
申请号：KR1020140040800
申请日：2014-04-04
申请人： 주식회사 강스템바이오텍 , 서울대학교산학협력단
发明人： 강경선 , 유경록
IPC分类号： C12N15/12 , C12N15/85 , C12N5/0797 , C12N5/10
CPC分类号： C12N5/0623 , A61K35/30 , A61K38/1709 , C12N2501/602 , C12N2501/998 , C12N2502/1352 , C12N2506/00 , C12N2506/025 , C12N2510/00 , G01N33/5058
摘要： The present invention relates to a method for producing induced neural stem cells reprogrammed from differentiated cells. The method for producing induced neural stem cells can produce inducted neural stem cells from non-neuronal cells using only two inducing factors of SOX2 and HMGA2; thereby producing the induced neural stem cells more efficiently than an existing producing method using four or five inducing factors. Also, the present invention has remarkably higher inducing efficiency and proliferation capacity than a case in which only the SOX2 gene is applied.
摘要翻译：本发明涉及一种用于产生从分化细胞重新编程的诱导性神经干细胞的方法。诱导神经干细胞的制备方法只能使用SOX2和HMGA2的两种诱导因子从非神经元细胞产生诱导的神经干细胞; 从而比使用四种或五种诱导因子的现有生产方法更有效地产生诱导的神经干细胞。此外，与仅施用SOX2基因的情况相比，本发明具有显着更高的诱导效率和增殖能力。

5. 发明公开

KR1020120013923A 제대혈 유래 줄기세포를 함유한 신경퇴행성 질환 예방 및 치료용 조성물 无效
标题翻译：用于治疗含有脐带血源性干细胞的神经变性疾病的组合物
公开(公告)号：KR1020120013923A
公开(公告)日：2012-02-15
申请号：KR1020110145187
申请日：2011-12-28
申请人： 서울대학교산학협력단
发明人： 강경선
IPC分类号： A61K35/51 , A61K47/32 , A61K47/10 , A61K9/00
CPC分类号： A61K35/51 , A61K9/0019 , A61K47/10 , A61K47/32
摘要： PURPOSE: A composition containing umbilical cord blood-derived stem cells is provided to suppress inflammation and to treat neurodegenerative diseases. CONSTITUTION: A method for preparing a composition for preventing or treating neurodegenerative diseases comprises: a step of culturing monocytes isolated from umbilicao cord blood in a SNU-1 or EGM-2 medium containing FBS, bFGF, ascorbic acid, EGF, hydrocortisone, IGF-I or VEGF and heparin to obtain stem cell in which ZNF281 is expressed; and a step of preparing a pharmaceutical composition containing the stem cells.
摘要翻译：目的：提供含有脐带血干细胞的组合物，以抑制炎症和治疗神经变性疾病。构成：制备用于预防或治疗神经变性疾病的组合物的方法包括：在含有FBS，bFGF，抗坏血酸，EGF，氢化可的松，IGF-1的SNU-1或EGM-2培养基中培养从脐带血中分离的单核细胞的步骤， I或VEGF和肝素获得其中表达ZNF281的干细胞; 以及制备含有干细胞的药物组合物的步骤。

6. 发明公开

KR1020110048502A Ｄｋｋ1 또는 ｓＦＲＰ4 억제제를 함유한 비만 예방용 조성물 无效
标题翻译：空值
公开(公告)号：KR1020110048502A
公开(公告)日：2011-05-11
申请号：KR1020110038627
申请日：2011-04-25
申请人： 서울대학교산학협력단
发明人： 강경선 , 박정란
IPC分类号： A61K39/395 , A61P3/04 , A61P3/00
CPC分类号： A61K35/28 , A61K39/39533 , Y10S514/909
摘要： PURPOSE: A composition containing Dkk1 inhibitor for preventing obesity is provided to suppress differentiation of mesenchymal stem cells to adipocytes. CONSTITUTION: A composition for preventing obesity contains Dkk 1 inhibitor. A method for suppressing differentiation of MSCs(mesenchymal stem cells) to adipocytes comprises a step of treating MSCs Dkk1 inhibitor. The Dkk1 inhibitor is an anti-Dkk1 antibody which neutralizes Dkk1 activation. The anti-Dkk1 antibody is a monoclonal antibody or polyclonal antibody. The composition is manufactured in the form of tablet, powder, pill, emulsion, solution, syrup, aerosol, or soft or hard gelatin capsule.
摘要翻译：目的：提供含有用于预防肥胖症的Dkk1抑制剂的组合物，以抑制间充质干细胞向脂肪细胞的分化。构成：用于预防肥胖的组合物含有Dkk1抑制剂。抑制MSC（间充质干细胞）分化为脂肪细胞的方法包括治疗MSCs Dkk1抑制剂的步骤。 Dkk1抑制剂是中和Dkk1激活的抗Dkk1抗体。抗Dkk1抗体是单克隆抗体或多克隆抗体。组合物以片剂，粉末，丸剂，乳剂，溶液，糖浆，气溶胶或软或硬明胶胶囊的形式制备。

7. 发明公开

KR1020100114230A 제대혈 유래 줄기세포를 함유한 신경퇴행성 질환 예방 및 치료용 조성물 有权
标题翻译：用于治疗含有脐带血导管干细胞的神经营养性疾病的组合物
公开(公告)号：KR1020100114230A
公开(公告)日：2010-10-25
申请号：KR1020090032654
申请日：2009-04-15
申请人： 서울대학교산학협력단
发明人： 강경선
IPC分类号： A61K35/51 , A61K9/00
CPC分类号： A61K35/51 , A61K9/0019
摘要： PURPOSE: A composition containing umbilical cord blood-derived stem cells for preventing and treating neurodegenerative diseases is provided to differentiate the stem cell to nerve cells and to suppress inflammation. CONSTITUTION: A composition for preventing or treating neurodegenerative diseases contains umbilical cord blood-derived stem cells. The stem cells is differentiated to nerve cells or myelin cells(MBP-positive). The growth of nerve cells is promoted by ERK1/2, PI3K, AKT, GSK3-beta, JAK2, or STAT3 signal transduction. The composition is formulated by transparent type or intravenous administration.
摘要翻译：目的：提供含有脐带血源性干细胞用于预防和治疗神经变性疾病的组合物，以将干细胞分化为神经细胞并抑制炎症。构成：用于预防或治疗神经变性疾病的组合物含有脐带血源性干细胞。干细胞分化成神经细胞或髓磷脂细胞（MBP阳性）。 ERK1 / 2，PI3K，AKT，GSK3-β，JAK2或STAT3信号转导促进神经细胞的生长。组合物通过透明型或静脉内给药配制。

8. 发明授权

KR102031712B1 그래핀 양자점을 포함하는 항염증용 조성물 有权
公开(公告)号：KR102031712B1
公开(公告)日：2019-10-14
申请号：KR1020170158753
申请日：2017-11-24
申请人： 서울대학교산학협력단 , 바이오그래핀 주식회사
发明人： 강경선 , 이병철 , 이진영 , 박종보
IPC分类号： A61K33/44 , A61K9/51 , A61K8/19 , A23L33/10 , A23K20/20 , A61Q19/00

9. 发明授权

KR101778953B1 비신경 세포를 이용한 유도신경줄기세포의 제조방법 有权
标题翻译：使用非神经元细胞制造诱导型神经干细胞的方法
公开(公告)号：KR101778953B1
公开(公告)日：2017-09-18
申请号：KR1020160064329
申请日：2016-05-25
申请人： 주식회사 강스템바이오텍 , 서울대학교산학협력단
发明人： 강경선 , 최순원 , 신지희 , 이승희
IPC分类号： C12N5/0797 , C12N5/0793 , C12N5/079 , C07H19/12
CPC分类号： C07H19/12 , C12N5/0623 , C12N5/0619 , C12N5/0622 , C12N2501/06 , C12N2501/11 , C12N2501/115
摘要： 본발명은비신경세포의유도신경줄기세포로의전환유도용조성물, 상기조성물을포함하는비신경세포의유도신경줄기세포로의전환유도용키트, 상기조성물또는키트를이용하여비신경세포로부터전환된유도신경줄기세포를제조하는방법및 상기방법에의해제조된유도신경줄기세포에관한것이다. 본발명에서제공하는비신경세포를유도신경줄기세포로전환시키는방법을사용하면, 유전자의변형없이도, 정상적인비신경세포를유도신경줄기세포로전환시킬수 있으므로, 자가신경줄기세포를이용한다양한신경질환의치료방법에널리활용될수 있을것이다.
摘要翻译：使用本发明高恩妃组合物衍生的神经干细胞的神经转换，转换以诱导来自非神经元诱导试剂盒神经转换包含该组合物诱导的组合物或试剂盒的非神经元细胞的神经干细胞本发明涉及通过上述方法制造干细胞的方法和诱导神经干细胞。本发明提供的将非神经元细胞转化为诱导型神经干细胞的方法可以在不修饰基因的情况下将正常非神经元细胞转化为诱导型神经干细胞，它会被广泛使用。

10. 发明公开

KR1020130116155A 피부세포로부터 기능성 인슐린 생산 세포의 직접 제조방법 有权
标题翻译：功能性胰岛素从人类纤维蛋白生成细胞的直接制备
公开(公告)号：KR1020130116155A
公开(公告)日：2013-10-23
申请号：KR1020120118708
申请日：2012-10-24
申请人： 주식회사 강스템바이오텍 , 서울대학교산학협력단
发明人： 강경선 , 서광원 , 김미현
IPC分类号： C12N5/071 , C12N15/85 , C12N5/10 , A61K35/12
摘要： PURPOSE: A method for directly producing functional insulin-producing cells from skin cells is provided to directly convert human somatic cells into insulin-producing cells without dedifferentiation into pluripotent cells and to obtain the insulin-producing cells which normally secrete insulin by glucose stimulation. CONSTITUTION: A method for producing insulin-producing cells comprises the step of promoting transcription of PDX-1 gene in somatic cells which do not produce insulin. The method directly converts the somatic cells into insulin-producing cells without dedifferentiation into cells with stemness. The step for promoting transcription of PDX-1 gene comprises the steps of transfecting cells by SMAD2 and transducing anti-Let7i by culturing the transfected cells for 2-10 days. [Reference numerals] (AA) Smad2 trait infection; (BB) Second day; (CC) FGM medium + 1% BSA; (DD) Anti-Let7i trait infection; (EE) EGM medium + 1% BSA; (FF) Seventh day; (GG) Glucose simulation index
摘要翻译：目的：提供从皮肤细胞直接产生功能性胰岛素生成细胞的方法，以将人体细胞直接转化成胰岛素产生细胞，而不去分化成多能细胞，并获得通过葡萄糖刺激通常分泌胰岛素的胰岛素产生细胞。构成：产生胰岛素的细胞的方法包括促进PDX-1基因在不产生胰岛素的体细胞中的转录的步骤。该方法直接将体细胞转化为产生胰岛素的细胞，而无需去分化成具有干细胞的细胞。促进PDX-1基因转录的步骤包括通过SMAD2转染细胞并通过培养转染细胞2-10天来转导抗Let7i的步骤。（附图标记）（AA）Smad2性状感染; （BB）第二天; （CC）FGM培养基+ 1％BSA; （DD）抗let7i性状感染; （EE）EGM培养基+ 1％BSA; （FF）第七天; （GG）葡萄糖模拟指数

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式